These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26196275)

  • 21. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ; Smyth HD
    Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
    Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Numerical Study on Particle Adhesion in Dry Powder Inhaler Device.
    Mitani R; Ohsaki S; Nakamura H; Watano S
    Chem Pharm Bull (Tokyo); 2020; 68(8):726-736. PubMed ID: 32741913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
    Young PM; Wood O; Ooi J; Traini D
    Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol.
    Kaialy W; Nokhodchi A
    Eur J Pharm Sci; 2015 Feb; 68():56-67. PubMed ID: 25497318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of a novel dry powder inhaler.
    Zhang X; Ma Y; Zhang L; Zhu J; Jin F
    Int J Pharm; 2012 Jul; 431(1-2):45-52. PubMed ID: 22543053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Process for overcoming drug retention in hard gelatin inhalation capsules.
    Saim S; Horhota ST
    Drug Dev Ind Pharm; 2002 Jul; 28(6):641-54. PubMed ID: 12149956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The filling of powdered herbs into two-piece hard capsules using hydrogenated cotton seed oil as lubricant.
    Aling J; Podczeck F
    Eur J Pharm Sci; 2012 Nov; 47(4):739-51. PubMed ID: 22960627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of dry powder aerosolization mechanisms in different channel designs.
    Chen L; Heng RL; Delele MA; Cai J; Du DZ; Opara UL
    Int J Pharm; 2013 Nov; 457(1):143-9. PubMed ID: 24055441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of inner physical properties on powder adhesion in inhalation capsules in case of a high resistance device.
    Otake H; Minami M; Yamaguchi M; Akiyama S; Inaba K; Nagai N
    Exp Ther Med; 2021 Dec; 22(6):1353. PubMed ID: 34659499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ; Kim SH; Raman V; Smyth HD
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.